Nov 212 min readSkyhawk Therapeutics to Present Preclinical Data of SKY-1214 Combination Treatment in Hematologic Cancers at the 66th American Society of Hematology Annual Meeting
Oct 242 min readSkyhawk Therapeutics Presents Compelling Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Oct 162 min readSkyhawk Therapeutics to Present Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Sep 113 min readSkyhawk Therapeutics to Present Additional Positive Topline Data from Parts A and B of Phase 1 Clinical Trial of SKY-0515 at European Huntington's Disease Network and Enroll-HD 2024
Jul 94 min readSkyhawk Therapeutics Announces Positive Topline Results of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction
Jul 12 min readSkyhawk Therapeutics Expands into State-of-the-Art Labs in its Basel, Switzerland Location
